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Accepted 23 December 2014; Published online 30 December 2014AbstractObjectives: Reviews of the handling of covariates in trials have explicitly excluded cluster randomized trials (CRTs). In this study, we
review the use of covariates in randomization, the reporting of covariates, and adjusted analyses in CRTs.
Study Design and Setting: We reviewed a random sample of 300 CRTs published between 2000 and 2008 across 150 English language
journals.
Results: Fifty-eight percent of trials used covariates in randomization. Only 69 (23%) included tables of cluster- and individual-level
covariates. Fifty-eight percent reported significance tests of baseline balance. Of 207 trials that reported baseline measures of the primary
outcome, 155 (75%) subsequently adjusted for these in analyses. Of 174 trials that used covariates in randomization, 30 (17%) included an
analysis adjusting for all those covariates. Of 219 trial reports that included an adjusted analysis of the primary outcome, only 71 (32%)
reported that covariates were chosen a priori.
Conclusion: There are some marked discrepancies between practice and guidance on the use of covariates in the design, analysis, and
reporting of CRTs. It is essential that researchers follow guidelines on the use and reporting of covariates in CRTs, promoting the validity of
trial conclusions and quality of trial reports.  2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).
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In cluster randomized trials (CRTs), preexisting groups
(clusters) of individuals (eg, family practices, hospitals,
communities, or schools) are randomized to intervention
or control treatment arms. This is in contrast to individually
randomized trials, where independent individuals are
randomly allocated to treatment arms. A cluster random-
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4.0/).including logistical or administrative convenience; to avoid
contamination; to improve compliance with treatment; to
enable the use of routine data only available at the cluster
level; or to evaluate an intervention that is applied at the
cluster level. Covariates are commonly used in the design
and analysis of randomized trials to promote balance be-
tween treatment arms and to improve precision and power
[1,2]. Unlike in individually randomized trials, covariates
in CRTs can exist at two levels that of the cluster and that
of the individual. A cluster-level covariate describes an
intrinsic characteristic of the cluster and is fixed for all in-
dividuals in the same cluster. An individual-level covariate
describes something about an individual and may vary
across individuals in the same cluster.
Specific recommendations are available with respect to
the use of covariates in the design and analysis of randomizeds article under the CC BY license (http://creativecommons.org/licenses/by/
ical Epidemiology 68 (2015) 603e609What is new?
Key findings
 Restricted randomization was used in around half
of cluster randomized trials (CRTs).
 Few trial reports included tables summarizing both
cluster-level and individual-level baseline covari-
ates, and over half of trials reported a significance
test of baseline balance.
 Adjusted analyses were common in CRTs, but au-
thors often did not report whether covariates have
been chosen before or after seeing the data.
What this adds to what was known?
 There are some marked discrepancies between
practice and guidance in the use of covariates in
CRTs.
What is the implication and what should change
now?
 Researchers and editors should note existing guide-
lines on the use and reporting of covariates in
CRTs.
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[3] include recommendations for the reporting of covari-
ates, and there is published guidance on adjusting for cova-
riates in analyses [1,4]. Austin et al. [5], Assmann et al. [6],
and Yu et al. [7] have reviewed adherence to recommenda-
tions with respect to the handling of covariates in random-
ized trials, but reviews have excluded CRTs. A review of
CRTs in primary care [8] included the use of matching or
stratification and reporting of baseline covariates. In this re-
view, we extend the work of Austin et al. [5] to CRTs,
where the multilevel nature of CRTs introduces additional
complexity in the handling of covariates.
CRTs usually randomize a smaller number of units, so
there is a greater risk of imbalance of covariates between
treatment arms. The use of restricted randomization, via
stratification, matching, or minimization, is therefore recom-
mended to help balance both cluster-level covariates and
individual-level covariates summarized at the cluster level,
when available, between treatment arms [9]. Failure to do
so may be a missed opportunity to improve validity and po-
wer by promoting balance in prognostic covariates [2,9].
The CONSORT extension for CRTs [10] recommends re-
porting both cluster-level and individual-level covariates as
applicable in tables comparing baseline characteristics be-
tween arms. Failure to report baseline distributions of covari-
ates limits the extent to which a reader of a trial report can
assess the validity of a trial’s findings and external relevance.There are clear recommendations against significance testing
of balance of covariates between treatment arms [1,11].
Including covariates that are strongly correlated with
outcome in an analysis can improve analytic power and sta-
tistical precision [1,12,13]. A baseline measure of the
outcome variable is often strongly correlated with outcome
and should be included in an adjusted analysis because it
represents an opportunity to improve the statistical power
of the analysis [14]. Covariates used in randomization
should also be adjusted for in an analysis [1,4].
The effects of adjusting for covariates in CRTs are more
complex than in individually randomized trials, as adjusting
for covariates may affect both the cluster-level and
individual-level residual variance of outcome. Only limited
guidance for choosing covariates in the analysis of CRTs
has been published [2,14]. As for individually randomized
trials, choosing covariates post hoc can invalidate conclu-
sions, although failure to report the method and justification
of choosing covariates prevents readers from assessing the
validity of adjusted analyses [4,11].
In this article, we review a random sample of published
CRTs with respect to the use of covariates in randomization,
the reporting of covariates by treatment arm, and adjustment
for covariates in analyses of the primary outcome. In
particular, we assess whether: (1) covariates were used in
randomization, (2) tables of baseline cluster-level and
individual-level covariates were presented, (3) significance
tests for baseline balance of covariates were avoided, (4) an
adjusted analysis of the primary outcome was reported, (5)
an analysis adjusting for baseline measure of the outcome
(if available) was reported, (6) an analysis adjusting for all co-
variates used in randomization was reported, and (7) all cova-
riates were reported to have been chosen a priori.
2. Methods
2.1. Trial sample
This review used a random sample of 300 CRTs previ-
ously identified using a published electronic search strategy
[15] implemented in MEDLINE. This sample has been
used to assess the impact of the CONSORT extension
[10] on the reporting and methodological quality of CRTs
[16]. The sample includes CRTs for which the main report
was published between 2000 and 2008, across 150 English
language journals. The journals include general medical
journals [eg, the New England Journal of Medicine
(NEJM), the Journal of the American Medical Association
(JAMA), The Lancet, and the British Medical Journal
(BMJ)] and various specialty journals (eg, the British Jour-
nal of Psychiatry, Diabetes Care, the International Journal
of Cancer, and the Journal of Nutrition).
2.2. Data abstraction
Two reviewers (N.W. and N.I.) independently read and
abstracted a defined list of items from each article. Any
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method was piloted on 15 articles, leading to clarifications
to the abstraction strategy. Twenty-five items were extracted
from each trial report, relating to: sample size and primary
outcome type (three items), use of covariates in randomization
(four items), reporting covariates at baseline (six items), ad-
justing for covariates in an analysis of the primary outcome
(eight items), and selection of covariates (two items). Ten
items related directly to recommendations made for handling
covariates; others were abstracted to provide general back-
ground characteristics of the trial and information about the
use of covariates. Definitions of variables abstracted and justi-
fication are described in the following paragraphs.2.3. Data abstracted
We describe each covariate as either a cluster- or
individual-level variable. The level is that at which the co-
variate is most naturally measured. This may not always be
the level at which it is reported or used in analysis. For
example, in a trial where general practitioners are the clus-
ters and their patients are the individuals, the number of
years since registration as a general practitioner is a
cluster-level covariate, whereas the age of a patient is an
individual-level covariate. A covariate measured entirely
or mostly on individuals not taking part in the trial and used
to describe some aspect of the cluster would be counted as
a cluster-level covariate. For example, in a trial where the
cluster is a general practice and only some patients in the
practice are recruited to the trial, the average age of all pa-
tients in a general practice is a cluster-level covariate. If a
single covariate was summarized and reported in multiple
ways (eg, mean age and proportion of patients above age
65), it was counted as one covariate.
We limited abstraction to analyses of the primary
outcome for each trial. The primary outcome was defined
to be the first primary outcome identified by the author. If
a primary outcome was not identified by the author, then
it was identified as: the outcome used in the sample size
calculation, the outcome identified by the article’s title, or
the first reported outcome in the article. To be included in
this review, an analysis had to include an estimate of treat-
ment effect plus a measure of uncertainty (such as a confi-
dence interval or standard error) or a P-value of a
significance test of no treatment effect.
We characterized covariates used in analyses as one of the
following: baseline measure of primary outcome, covariate
used in randomization (eg, stratification, minimization, or
matching factors), and any other covariate. When a study re-
ported change from baseline as the primary outcome, we
counted this as an attempt to adjust for the baseline measure
of outcome, acknowledging that this is not the recommended
approach [1].We considered covariates used in randomization
separately from other covariates because these should be
adjusted for in the analysis [1,4] and to enable comparison
with previous methodological reviews [5].When considering analyses adjusted for covariates other
than the baseline measure of outcome or covariates used in
randomization, only the analysis identified by the author as
the main adjusted analysis (or the first reported if a main
adjusted analysis was not identified) was evaluated. Sub-
group analyses were not considered. Any reason given for
selecting covariates for multivariate analysis was consid-
ered as justification given.
The reported method for selecting covariates for
adjusted analyses was considered post hoc if the article
described a method where covariates were chosen after
observation of any trial data. For example, selecting cova-
riates due to an observed imbalance between treatment
groups, or using a covariate selection algorithm, were post
hoc methods. If the article reported that covariates were
chosen before any data were observed, for example, they
were prespecified in an analysis plan, then the reported
method of choosing covariates is a priori. In all other cases,
the method was considered unclear.3. Analysis
Results are presented using descriptive statistics and
include two sets of results by subgroups, which were cho-
sen post hoc for further investigation. We explored whether
the use of covariates in randomization and adjusting for co-
variates at cluster and individual level varied according to
the number of clusters in the trial. We explored whether re-
porting covariates in baseline tables, using statistical tests
of baseline balance, and reporting choosing covariates a
priori differed for trials published in high-impact journals
compared with other journals.
In the first stratified analysis, three subgroups were
defined by mean number of clusters per treatment arm.
Subgroups were formed by the lower quartile, upper quar-
tile, and remaining trials: five or fewer clusters per arm,
from 5.5 to 23 clusters per arm, and more than 23 clusters
per arm. These subgroups contained 75, 147, and 71 tri-
als, respectively. In this analysis, seven trials were
excluded as the mean number of clusters per treatment
arm could not be calculated because either the total num-
ber of individuals or the number of clusters in the trial
was not reported.
In the second stratified analysis, two subgroups were
defined by the impact factor of the publishing journal.
Impact factors were obtained from journal citation reports
(ISI Web of Science, 2009). We defined high-impact jour-
nals as those with impact factor greater than 10, which in
this sample are the New England Journal of Medicine
(NEJM); the Journal of the American Medical Association
(JAMA); The Lancet; Annals of Internal Medicine; PLOS
Medicine; and the British Medical Journal (BMJ). Fifty-
one trial reports in the sample were published in these
high-impact journals. The remaining 249 trial reports were
published in other journals.
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4.1. Trial characteristics
Characteristics of the 300 trial reports used in this re-
view are summarized in table number 2 of Ivers et al. [16].4.2. Randomization
Details with respect to the use of covariates in random-
ization are presented in Table 1. In 174 (58.0%) of the 300
trials, at least one covariate was used in randomization. In
130 trials (43.3%), at least one covariate other than cluster
location and cluster size was used. In 118 trials (39.3%),
only cluster-level covariates were used.
In the 124 trials that used cluster-level covariates in
randomization, 74 (59.7%) used one cluster-level covariate,
24 (19.4%) used two, and 26 (21.0%) used between three
and nine. Only 12 trials used individual-level covariates
in randomization of which nine (75%) used only one
individual-level covariate.
Of 277 trials that were conducted in more than one loca-
tion, authors of 50 (18.1%) attempted to balance for cluster
location in randomization (3 of 277 were unclear). Of 285
trials with varying cluster sizes, authors of 51 (17.9%)Table 1. Use of covariates in randomization, reporting of covariates, and us
Review item
Use of covariates in randomization
Covariates used in randomization
Types of covariates used in randomization
Cluster location
Cluster size
Other
Only cluster-level covariates
Only individual-level covariates
Both cluster- and individual-level covariates
None
Unclear
Reporting of covariates
Trial report includes a table reporting
Cluster-level covariates only
Individual-level covariates only
Cluster- and individual-level covariates
None
Baseline measure of primary outcome reported
Significance test of balance of a covariate between treatment arms
Covariates used in analysis
Trial report includes
An unadjusted analysis of the primary outcome
At least one adjusted analysis of the primary outcome
Trial report includes an analysis of the primary outcome adjusting for
Baseline measure of outcome
All covariates used in randomization
Other covariates
When covariates were reported to be chosen
A priori
Post hoc
Both a priori and post hoc
Not reported or unclear
Justification given for the selection of covariatesattempted to balance cluster size in randomization (4 of
285 were unclear). Of 263 trials with multiple location
and variable cluster size, authors of 12 (4.6%) attempted
to balance both location and cluster size in randomization.
4.3. Reporting of baseline covariates
Of 300 trial reports, 69 (23.0%) included tables report-
ing both cluster- and individual-level covariates by treat-
ment arm, whereas 158 (52.7%) included a table of
individual-level covariates only. Further details are given
in Table 1. The number of cluster-level covariates described
in a table or in the text ranged from 1 to 19 (if nonzero),
with a median of 3. The number of individual-level covari-
ates described in a table or in the text ranged from 1 to 28
(if nonzero), with a median of 7.
Of 300 trial reports, 207 (69%) reported a baseline mea-
sure of the primary outcome. A significance test of the bal-
ance of a covariate between treatment arms was reported or
referred to in 166 trial (55.3%) reports.
4.4. Adjusted analyses
Of 300 trial reports, 219 (73.0%) included at least one
adjusted analysis of the primary outcome. Of 207 triale of covariates in analysis
Number of trials/relevant trials (%) Note
174/300 (58.0) (3/300 unclear)
50/277 (18.1) (3/277 unclear)
51/285 (17.9) (4/285 unclear)
118/300 (39.3)
6/300 (2.0)
6/300 (2.0)
167/300 (55.7)
3/300 (1.0)
13/300 (4.3)
158/300 (52.7)
69/300 (23.0)
60/300 (20.0)
207/300 (69.0)
166/300 (55.3)
130/300 (43.3)
219/300 (73.0)
155/207 (74.9)
30/174 (17.2)
140/300 (46.7)
71/219 (32.4)
37/219 (16.9)
18/219 (8.2)
93/219 (42.5)
73/219 (33.3)
Table 2. Covariates used in randomization and covariates used in an adjusted analysis, by subgroup of mean number of clusters per treatment arm
Review item
Mean number of clusters per treatment arm
1 to 5 (%) 5.5 to 23 (%) 23.5 to 3,510.5 (%)
Types of covariates used in randomization (excluding cluster location and cluster size)
Only cluster level 18/75 (24.0) 73/147 (49.7) 26/71 (36.6)
Only individual level 2/75 (2.7) 3/147 (2.0) 1/71 (1.4)
Both cluster and individual level 2/75 (2.7) 3/147 (2.0) 1/71 (1.4)
None 52/75 (69.3) 66/147 (44.9) 43/71 (60.6)
Unclear 1/75 (1.3) 2/147 (1.4) 0/71 (0.0)
Covariates (other than baseline measure of outcome and covariates used in randomization) included in an adjusted analysis
Cluster only 0/33 (0.0) 1/71 (1.4) 6/34 (17.6)
Individual only 25/33 (75.8) 50/71 (70.4) 23/34 (67.6)
Both cluster and individual level 5/33 (15.2) 20/71 (28.2) 4/34 (11.8)
Unclear 3/33 (9.1) 0/71 (0.0) 1/34 (2.9)
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outcome, 155 (74.9%) included an analysis adjusting for
a baseline measure of the outcome. Of 174 trials that used
covariates (including cluster size and location) in random-
ization, 30 (17.2%) included an analysis adjusting for all
covariates used in randomization. These results are summa-
rized in Table 1. Seven trial reports did not include any un-
adjusted or adjusted analysis of the primary outcome,
according to our criteria.
There were 140 trials (46.7%) that included an analysis
adjusting for covariates other than baseline measure of
outcome or covariates used in randomization. Of these
140 adjusted analyses, 7 (5.0%) included only cluster-
level covariates, whereas 100 (71.4%) adjusted for only
individual-level covariates. In 29 analyses (20.7%), both
cluster- and individual-level covariates were included. In
four (2.9%) of these trials, it was unclear which level of co-
variates had been included. When included, the number of
cluster-level covariates ranged from 1 to 8, with a median
of 1. Likewise, the number of individual-level covariates
included in an adjusted analysis ranged from 1 to 28, with
a median of 3.
4.5. Choosing covariates
Of the 219 trial (73.0%) reports that included an
adjusted analysis of the primary outcome, in 71 authors
(32.4%) reported choosing covariates a priori, but in 93
(42.4%), it was not reported when covariates adjusted for
had been chosen. In 73 trial (33.3%) reports, authors gave
some justification for the choice of covariates.
4.6. Subgroup resultsdnumber of clusters
The results from the subgroup analyses based on trial size
are summarized in Table 2. At least one covariate other than
cluster location and cluster sizewas used in randomization in
22 of 75 trials (29%) with five or fewer clusters per treatment
arm. In trials withmore than 23 clusters per treatment arm, 28
of 71 (39%) balanced on covariates other than cluster loca-
tion or cluster size. In the remaining 147 trials, 79 (53.7%)
used other covariates in randomization.Thirty-three (44%) of the 75 smallest trials included an
analysis adjusting for covariates other than baseline mea-
sure of outcome and covariates used in randomization. Five
(15%) of those adjusted for cluster-level covariates. Of the
71 largest trials (more than 23 clusters per arm), 34 (48%)
reported an analysis adjusting for other covariates, and 10
(29%) of those analyses used cluster-level covariates. Of
the 147 remaining trials, 71 (48%) included an analysis ad-
justing for other covariates, with 21 (30%) using cluster-
level covariates.
4.7. Subgroup resultsdjournal impact factor
The results described in this section are summarized in
Table 3. Reports published in journals with high-impact
factors showed higher adherence to three guidelines as-
sessed. In particular, tables reporting both cluster- and
individual-level covariates were included in 24 of 50 trial
reports (48%) in high-impact journals, compared with 45
of 250 trial reports (18.0%) in other journals; a significance
test of balance of a covariate between treatment arms was
reported or referred to in 17 of 50 trial reports (34%) in
high-impact journals, compared with 149 of 250 trial re-
ports (59.6%) in other journals; and 7 (21%) included an
analysis adjusting for all covariates used in randomization
compared with 23 (16.3%) in other journals.
Of 30 trial reports in high-impact journals that reported a
baseline measure of the primary outcome, 21 (70%)
included an analysis adjusting for a baseline measure of
outcome, compared with 134 (75.7%) of 177 in other jour-
nals. In 19 high-impact factor journal reports (51.4%), it
was unclear when covariates adjusted for in the analysis
had been chosen compared with 74 (40.7%) in other
journals.5. Discussion
In CRTs, baseline balance of covariates may be a greater
concern than in individually randomized trials [9]. Despite
recommendations to use restricted randomization, espe-
cially in smaller CRTs [9], over 40% of authors did not
Table 3. Reporting of covariates and use of covariates in analysis, by subgroup defined by journal impact factor
Review item High-impact journals (impact factor O10) (%) Other journals (%)
Reporting of covariates
Trial report includes a table reporting
Cluster-level covariates only 2/50 (4.0) 11/250 (4.4)
Individual-level covariates only 18/50 (36.0) 140/250 (56.0)
Cluster- and individual-level covariates 24/50 (48.0) 45/250 (18.0)
None 6/50 (12.0) 54/250 (21.6)
Significance test of balance of a covariate 17/51 (34.0) 149/250 (59.6)
Covariates used in analysis
Trial report includes an adjusted analysis of the primary outcome 37/50 (74.0) 182/250 (72.8)
Trial report includes an analysis of the primary outcome adjusting for
Baseline measure of outcome 21/30 (70.0) 134/177 (75.7)
All covariate used in randomization 7/33 (21.2) 23/141 (16.3)
Other covariates 22/50 (44.0) 118/250 (47.2)
When covariates were reported to be chosen
A priori 12/37 (32.4) 59/182 (32.4)
Post hoc 5/37 (13.51) 32/182 (17.6)
Both a priori and post hoc 1/37 (2.7) 17/182 (9.3)
Unclear 19/37 (51.4) 74/182 (40.7)
Justification given for the selection of covariates 12/37 (32.4) 61/182 (33.5)
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randomization in a review of CRTs in primary care [8].
Furthermore, attempting to use restricted randomization
to achieve balance on individual-level covariates was rare,
although balance of both cluster-level and individual-level
covariates is important in a CRT [9].
Although 80% of trials included at least one table report-
ing covariates by treatment group, less than 25% included
tables for both cluster- and individual-level covariates at
baseline, as recommended by CONSORT guidelines [10].
The proportion of trial reports including a table of
individual-level covariates by treatment arm at baseline
was slightly higher in high-impact journals (84%). This
compares to 96.5% and 96% in the individually randomized
trials reviewed by Austin et al. [5] and Saquib et al. [17],
respectively. Those reviews included only articles pub-
lished in selections of journals with high-impact factors.
This suggests greater adherence in trial reports in high-
impact journals, rather than a difference in reporting be-
tween CRTs and individually randomized trials.
More than half of sampled CRTs (55.3%) reported a sig-
nificance test of baseline balance, despite clear recommen-
dations against this practice [1,11]. Although these
recommendations strictly apply to individually randomized
trials, the argument extends directly to not testing baseline
balance of covariates that can only be imbalanced by
chance. This practice appears less common in high-
impact journal reports (34%) and compares to 38.2% and
46% in the reviews of individually randomized trials by
Austin et al. [5] and Saquib et al. [17], respectively.
At least one adjusted analysis of the primary outcome
was reported in 73% of CRT reports. Adjusted analyses
of the primary outcome using the baseline measure of
outcome (as recommended by Murray [14]) were conduct-
ed in 74.9% of trials that reported baseline values of the
outcome. An analysis adjusting for other covariates (notbaseline measure of outcome or covariates used in random-
ization) was reported in almost half (46.7%) of trial reports.
This compares to 34.2% of individually randomized trials
in the review by Austin et al. [5], which included analyses
adjusting for covariates other than baseline measure of
outcome and covariates used in randomization.
In one-quarter of adjusted analyses, some or all covari-
ates were reportedly chosen post hoc, defying guidance
for choosing all covariates a priori [2]. In 93 cases
(42.5%), it was not reported when the covariates adjusted
for in the analysis had been chosen. This does not allow
any assessment of the validity of selecting covariates but
is less common than in the individually randomized trials
considered by Austin et al. [5] and Yu et al. [7] (67% and
75.6% of trial reports). Only a third of CRT reports gave
any justification for covariate choice, compared with
41.7% and 73.6% of individually randomized trials in the
reviews by Assmann et al. [6] and Yu et al. [7], respectively.
This review is limited by the age of the included trial re-
ports, ranging from 6 to 14 years old. It is plausible that
more recently published CRTs could show different charac-
teristics. In addition, we limited abstraction to one primary
outcome and one adjusted analysis from each trial report.
Therefore, the number of adjusted analyses actually con-
ducted is almost certainly greater than we report. We did
not carry out any hypothesis testing or inferential analysis,
as we sought to describe practice and had no a priori hy-
potheses. Similarly, our results by subgroup were descrip-
tive as we had no a priori hypotheses. Finally, no
inferences were made with respect to the appropriateness
of methods used for randomization or adjusting for covari-
ates in any trial as there is uncertainty regarding ideal
strategies.
In summary, there are some marked discrepancies be-
tween practice and guidance for CRTs with regard to using
covariates in randomization, reporting covariates, testing
609N. Wright et al. / Journal of Clinical Epidemiology 68 (2015) 603e609balance, and methods of choosing covariates. As with the
reviews of individually randomized trials, there is inade-
quate adherence to clear guidance such as not using statis-
tical tests of baseline balance of covariates and choosing
covariates to be used in an adjusted analysis a priori. There
appears to be better adherence to some recommendations
among CRTs published in high-impact journals, compared
with CRTs reported in other journals. Recommendations to
use restricted randomization and to report both cluster-level
and individual-level covariates are not well followed. It is
essential that researchers conducting CRTs follow existing
guidelines on the use and reporting of covariates to ensure
validity of trial conclusions and aid readers in assessing the
quality and results of a trial. Readers should be aware of
limitations in trials that do not adhere to such guidelines.
Further research is needed into the effects of adjusting for
cluster- and individual-level covariates in the analysis of
CRTs, and further guidance is needed for choosing covari-
ates in CRTs.References
[1] CPMP. Points to consider on adjustment for baseline covariates
(CPMP/EWP/2863/99). London: EMEA; 2003.
[2] Raab GM, Butcher I. Balance in cluster randomized trials. Stat Med
2001;20:351e65.
[3] Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT
2010 Statement: updated guidelines for reporting parallel group rand-
omised trials. Trials 2010;11:32.
[4] Raab GM, Day S, Sales J. How to select covariates to include in the
analysis of a clinical trial. Control Clin Trials 2000;21:330e42.
[5] Austin PC, Manca A, Zwarenstein M, Juurlink DN, Stanbrook MB. A
substantial and confusing variation exists in handling of baseline co-
variates in randomized controlled trials: a review of trials published
in leading medical journals. J Clin Epidemiol 2010;63:142e53.[6] Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and
other (mis)uses of baseline data in clinical trials. Lancet 2000;355:
1064e9.
[7] Yu L-M, Chan A-W, Hopewell S, Deeks JJ, Altman DG. Reporting
on covariate adjustment in randomised controlled trials before and af-
ter revision of the 2001 CONSORT statement: a literature review. Tri-
als 2010;11:59.
[8] Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC.
Lessons for cluster randomized trials in the twenty-first century: a
systematic review of trials in primary care. Clin Trials 2004;1:80e90.
[9] Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K,
et al. Allocation techniques for balance at baseline in cluster random-
ized trials: a methodological review. Trials 2012;13:120.
[10] Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT
Group. Consort 2010 statement: extension to cluster randomised tri-
als. BMJ 2012;345:e5661.
[11] Senn S. Testing for baseline balance in clinical trials. Stat Med 1994;
13:1715e26.
[12] Roozenbeek B, Maas AIR, Lingsma HF, Butcher I, Lu J,
Marmarou A, et al. Baseline characteristics and statistical power in
randomized controlled trials: selection, prognostic targeting, or co-
variate adjustment? Crit Care Med 2009;37(10):2683e90.
[13] Hernandez AV, Steyerberg EW, Habbema JDF. Covariate adjustment
in randomized controlled trials with dichotomous outcomes increases
statistical power and reduces sample size requirements. J Clin Epide-
miol 2004;57:454e60.
[14] Murray DM. Design and analysis of group-randomized trials. New
York: Oxford University Press; 1998.
[15] Taljaard M, McGowan J, Grimshaw JM, Brehaut JC, McRae A,
Eccles MP, et al. Electronic search strategies to identify reports of
cluster randomized trials in MEDLINE: low precision will improve
with adherence to reporting standards. BMC Med Res Methodol
2010;10:15.
[16] Ivers NM, Taljaard M, Dixon S, Bennett C, McRae A, Taleban J,
et al. Impact of CONSORT extension for cluster randomised trials
on quality of reporting and study methodology: review of random
sample of 300 trials, 2000-8. BMJ 2011;343:d5886.
[17] Saquib N, Saquib J, Ioannidis JPA. Practices and impact of primary
outcome adjustment in randomized controlled trials: meta-
epidemiologic study. BMJ 2013;347:f4313.
